SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Provectus Pharmaceuticals Inc.
PVCT 0.0649+0.6%Nov 13 3:42 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Joseph B. Schmidt who wrote (12389)9/7/2013 7:22:11 AM
From: NTTG1 Recommendation

Recommended By
Pogeu Mahone

   of 13111
 
not really, think about it for a bit.... Product A is approved for use in stage III and IV MM, product B is approved for non-aggressive stage III and has PII data that they are not effective in stage IV disease.....which drug does a patient want to be treated with? Which drug does a physician want to use in his/her practice.

Think about it some more...... what % of potential patients do you loose with a drug that is not approved for aggressive disease

Now, calculate the commercial break even point

Dont bank too hard on 'off label' use, that is a dying practice pattern in the growing world of evidence based medicine and managed medicine
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News